Abstract：Objective: To explore the correlation between serum insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9) levels and disease severity in patients with combined pulmonary fibrosis and emphysema (CPFE). Methods: A total of 58 patients with CPFE in the hospital were enrolled as CPFE group, 30 patients with pulmonary fibrosis were enrolled as pulmonary fibrosis group, 30 patients with simple emphysema were enrolled as emphysema group, and 30 healthy controls were enrolled as control group between January 2015 and December 2021. The levels of serum IGF-1, VEGF and MMP-9 were detected, and their differences in different groups were compared. The relationship between serum IGF-1, VEGF, MMP-9 and pulmonary function indexes [forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC], blood gas indexes [partial pressure of arterial blood oxygen (PaO2), partial pressure of carbon dioxide (PaCO2)] was analyzed. Results: The levels of serum IGF-1, VEGF and MMP-9 were the highest in pulmonary fibrosis group, followed by CPFE group, emphysema group and control group (P<0.05). PaO2 level in CPFE group was lower than that in pulmonary fibrosis group and emphysema group (P<0.05), and FEV1/FVC was lower than that in pulmonary fibrosis group and emphysema group (P<0.05). The levels of serum IGF-1, VEGF and MMP-9 was negatively correlated with PaO2 (r=-0.379, -0.357, -0.283, P<0.05), while positively correlated with PaCO2 (r=0.394, 0.302, 0.330, P<0.05). The levels of serum IGF-1, VEGF and MMP-9 was negatively correlated with FEV1 and FEV1/FVC (r=-0.301, -0.246, -0.251, -0.411, -0.373, -0.310, P<0.05), while positively correlated with FVC (r=0.271, 0.253, 0.234, P<0.05). Conclusion: The expression levels of serum IGF-1, VEGF and MMP-9 are high in CPFE patients, which are negatively correlated with lung function, while positively correlated with partial pressure of blood oxygen. They can reflect pulmonary function and limitation degree of ventilation function to a certain extent.
戴晓瑛, 王志峰, 颜洪顺, 符之月. 肺纤维化合并肺气肿患者血清IGF-1 VEGF MMP-9表达变化及其与肺功能水平的相关性分析[J]. 河北医学, 2023, 29(3): 393-397.
DAI Xiaoying, WANG Zhifeng, YAN Hongshun, et al. Correlation between Serum IGF-1 VEGF MMP-9 Levels and Disease Severity in Patients with Combined Pulmonary Fibrosis and Emphysema. HeBei Med, 2023, 29(3): 393-397.
[1] 吴苏佶,谢敏.肺纤维化合并肺气肿综合征发病机理与研究进展[J].四川医学,2019,40(3):310-314. [2] Roux A,Sage E,Cerf C,et al.Evolution and progress of lung transplantation:an analysis of a cohort of 600 lung transplant patients at the Hospital Foch[J].Rev Mal Respir,2019,36(2):142-154. [3] 林敏杰,张英为,邱玉英.肺纤维化合并肺气肿的研究进展[J].临床肺科杂志,2020,25(3):445-449. [4] 张茹玉,叶潘,李月潞,等.抗乳腺癌基质金属蛋白酶9类抑制剂的分子设计研究[J].成都医学院学报,2021,16(5):571-576. [5] 中华医学会呼吸病学分会.特发性肺(间质)纤维化诊断和治疗指南(草案)[J].中华结核和呼吸杂志,2002,25(7):387-389. [6] Ju J,Li R,Gu S,et al.Impact of emphysema heterogeneity on pulmonary function[J].PLos One,2014,9(11):e113320. [7] 曾绮娴,罗勤,赵青,等.肺纤维化合并肺气肿综合征并发肺动脉高压患者的临床特征分析[J].中国循环杂志,2020,35(10):1000-1005. [8] 李竹霞,汤亦凌,雷银兰,等.儿童特发性肺纤维化临床特征、远期预后及肺功能改变[J].中华实用儿科临床杂志,2021,36(16):1240-1244. [9] 谢佳峻,徐维国,吴君华,等.外周血IGF-1、PAI-1和TGF-β1在肺间质纤维化合并肺气肿患者中的表达及意义分析[J].实用心脑肺血管病杂志,2019,15(S2):7-10. [10] Qun L,Wang JJ,Xu CQ,et al.Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways.[J].Mol Med,2020,26(1):49. [11] 敬小莉,孙续禄,张俊,等.黄芪提取物对特发性肺纤维化小鼠的治疗效果及TGF-β、VEGF分析[J].中华中医药学刊,2021,39(4):248-250. [12] Lee FY,Lee MS,Wallace CG,et al.Short-interval exposure to ambient fine particulate matter (PM2.5) exacerbates the susceptibility of pulmonary damage in setting of lung ischemia-reperfusion injury in rodent:Pharmacomodulation of melatonin[J].Biomed Pharmacother,2019,113(6):96-99.
2023, Vol. 29 
冀公网安备13080202000786号